RP2 + Pegfilgrastim + Filgrastim
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Adenocarcinoma
Conditions
Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Trial Timeline
Apr 1, 2026 → Nov 1, 2029
NCT ID
NCT07059611About RP2 + Pegfilgrastim + Filgrastim
RP2 + Pegfilgrastim + Filgrastim is a phase 2 stage product being developed by Replimune for Gastric Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07059611. Target conditions include Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma.
What happened to similar drugs?
5 of 20 similar drugs in Gastric Adenocarcinoma were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07059611 | Phase 2 | Recruiting |
Competing Products
20 competing products in Gastric Adenocarcinoma